Key Highlights

  • Monash IVF Group (ASX:MVF) shares fell 4.70% to $0.71 on 24 August 2026 after the company postponed its FY2026 results release.
  • The audit of FY2026 financial statements is taking longer than anticipated, pushing the results date to 31 August 2026.
  • On 12 June 2026, the company had already flagged softer earnings, with FY26 Underlying NPAT expected between $17 million and $18 million.
  • Stimulated cycle volumes across the Australian ART market fell 4.7% on a rolling three-month basis to the end of April, though Monash IVF grew national Market Share to 20.1%.

Shares of Monash IVF Group Limited (ASX:MVF) declined 4.70%, or 3.5 cents, to $0.71 in trading on 24 August 2026, after the company informed the market that its FY2026 results would not be released as originally scheduled. The company had been due to report on 24 August 2026, but advised that the audit of its FY2026 financial statements is taking longer than anticipated. Management is now working with the company's auditor to complete the remaining audit procedures, with the FY2026 results now expected to be released on 31 August 2026.

The announcement did not provide additional detail on the specific nature of the audit delay, other than confirming that the extra time is required to finalise the remaining procedures alongside the auditor. The postponement comes at a sensitive time for the company, which had already flagged a weaker Earnings outlook for the financial year in an update issued in June 2026.

June Update Had Already Signalled Softer Earnings

In a market and trading update issued on 12 June 2026, Monash IVF advised that it now expects FY26 Underlying NPAT to be in the range of $17 million to $18 million. The company attributed the revised outlook primarily to lower than expected Australian ART market activity in the second half of the financial year.

According to Medicare data cited in the update, stimulated cycle volumes across the Australian ART market were down 4.7% on a rolling three-month basis to the end of April 2026, compared with the prior corresponding period. The company noted that the impact of these adverse market conditions continued through May and June 2026.

Despite the broader market softness, Monash IVF reported that it had increased its national market share by 1.0 percentage point to 20.1% on a rolling three-month basis compared with the prior corresponding period, with some states recording more significant market share gains than others.

International Operations and Clinical Network Expansion

The June update also highlighted growth in Monash IVF's international operations, with second-half FY26 volumes expected to be materially higher than in the prior corresponding period. The company said it had continued to strengthen its clinical network, including the addition of key fertility specialists in Victoria and New South Wales, following the appointment of Fleur Cattrall as the company's inaugural Chief Medical Officer.

Operational and cost efficiency initiatives that were announced at the company's half-year results were described as being well underway. However, the company noted that given the timing of implementation, these initiatives had a limited impact on FY26 earnings, with a greater contribution expected in FY27. Chief Executive Officer Victoria Atkinson said the company had increased its Australian stimulated cycle market share during the period and had taken steps to reduce costs and improve operational performance, with these initiatives expected to contribute more meaningfully in FY27.

Conclusion

Monash IVF's share price decline on 24 August 2026 reflects investor reaction to the postponement of its FY2026 results, following an earlier downgrade to its earnings outlook in June that pointed to softer Australian ART market activity. While the company has reported gains in national market share and growth in its international operations, the extended audit timeline introduces additional uncertainty ahead of the rescheduled results announcement on 31 August 2026, when further detail on the FY2026 performance and outlook is expected to be provided to shareholders.